Best practice in research - Overcoming common challenges in phytopharmacological research.
💡 한 문장 핵심
연구의 모범 사례 - 식물약리학 연구의 일반적 난제 극복.
4/5 보강
TL;DR
This consensus document provides a perspective on what constitutes best practice in pharmacological research on bioactive preparations derived from natural sources, providing a perspective of what the leading specialist journals in the field consider as the core characteristics of good research.
연도별 인용 (2019–2026) · 합계 537
OpenAlex 토픽 ·
Herbal Medicine Research Studies
Magnolia and Illicium research
Medicinal Plants and Bioactive Compounds
Abstract 🌐 Abstract
[BACKGROUND] The pharmacology, toxicology and pharmacokinetics of bioactive preparations derived from natural sources has become a flourishing field of research. However, researching complex extracts and natural products faces numerous challenges. More broadly in recent years the critique of pharmacological research, and specifically its design, the methods used and reporting has intensified.
[AIMS] This consensus document provides a perspective on what constitutes best practice in pharmacological research on bioactive preparations derived from natural sources, providing a perspective of what the leading specialist journals in the field consider as the core characteristics of good research.
[APPROACH ('METHODS')] The editors-in-chief of seven journals developed this best practice statement in an iterative process. A first draft of the guidelines (prepared by MH) was then discussed and amended by the other editors.
[OUTCOMES] Core to this contribution is a table which provides detailed advice including simple points like a use of appropriate controls and the full taxonomic validity of the material under investigation (see also below), to the relevance of the model for the question being researched (e.g., can specific in silico or in vitro models really address the species anti-inflammatory activity?). Therefore, obviously, researchers must pay detailed attention to reporting and discussing such studies. This information must be discussed critically (as much as it is possible based on the published papers) in terms of their scientific quality and validity. While these points are obvious, as editors, we are aware that they are often not properly implemented.
[CONCLUSION] We call for an approach which incorporates a careful design, meticulous execution and a detailed reporting of studies focusing on the pharmacology/bioactivity of bioactive preparations. Clearly testable research questions must be developed and investigated experimentally. As the founder of pharmacology Claude Bernard put it already in 1865: '…. either the experimenter's hypothesis will be disproved or it will be proved by experiment. When experiment disproves its preconceived ideas, the experimenter must discard or modify it.'
[AIMS] This consensus document provides a perspective on what constitutes best practice in pharmacological research on bioactive preparations derived from natural sources, providing a perspective of what the leading specialist journals in the field consider as the core characteristics of good research.
[APPROACH ('METHODS')] The editors-in-chief of seven journals developed this best practice statement in an iterative process. A first draft of the guidelines (prepared by MH) was then discussed and amended by the other editors.
[OUTCOMES] Core to this contribution is a table which provides detailed advice including simple points like a use of appropriate controls and the full taxonomic validity of the material under investigation (see also below), to the relevance of the model for the question being researched (e.g., can specific in silico or in vitro models really address the species anti-inflammatory activity?). Therefore, obviously, researchers must pay detailed attention to reporting and discussing such studies. This information must be discussed critically (as much as it is possible based on the published papers) in terms of their scientific quality and validity. While these points are obvious, as editors, we are aware that they are often not properly implemented.
[CONCLUSION] We call for an approach which incorporates a careful design, meticulous execution and a detailed reporting of studies focusing on the pharmacology/bioactivity of bioactive preparations. Clearly testable research questions must be developed and investigated experimentally. As the founder of pharmacology Claude Bernard put it already in 1865: '…. either the experimenter's hypothesis will be disproved or it will be proved by experiment. When experiment disproves its preconceived ideas, the experimenter must discard or modify it.'
This consensus document provides a perspective on what constitutes best practice in pharmacological research on bioactive preparations derived from natural sources, providing a perspective of what the
APA 7
Heinrich, M., Appendino, G., Efferth, T., R, F., Izzo, A. A., Kayser, O., Pezzuto, J. M., & Viljoen, A. (2020). Best practice in research - overcoming common challenges in phytopharmacological research.. Journal of ethnopharmacology, 246, 112230. https://doi.org/10.1016/j.jep.2019.112230
Vancouver
Heinrich M, Appendino G, Efferth T, R F, Izzo AA, Kayser O, et al. Best practice in research - Overcoming common challenges in phytopharmacological research. Journal of ethnopharmacology. 2020;246:112230. doi:10.1016/j.jep.2019.112230
AMA 11
Heinrich M, Appendino G, Efferth T, R F, Izzo AA, Kayser O, et al. Best practice in research - Overcoming common challenges in phytopharmacological research. Journal of ethnopharmacology. 2020;246:112230. doi:10.1016/j.jep.2019.112230
Chicago
Heinrich, M., Appendino, G., Efferth, T., R, F., Izzo, A. A., Kayser, O., Pezzuto, J. M., and Viljoen, A.. 2020. "Best practice in research - Overcoming common challenges in phytopharmacological research." Journal of ethnopharmacology 246: 112230. https://doi.org/10.1016/j.jep.2019.112230
MLA 9
Heinrich, M., et al. "Best practice in research - Overcoming common challenges in phytopharmacological research." Journal of ethnopharmacology, vol. 246, 2020, pp. 112230. doi:10.1016/j.jep.2019.112230.
PMID
31526860 ↗
추출된 의학 개체 (NER)
해부
추출물 extracts
상태/진단
pharmacology/bioactivity
전체 NER 표 보기
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 해부 | extracts
|
추출물 | scispacy | 1 | |
| 약물 | [BACKGROUND]
|
scispacy | 1 | ||
| 질환 | pharmacology/bioactivity
|
scispacy | 1 |
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
인용 관계
그래프 OA 노드: 1/1 (100%)
· 참조 0편 · 후속 1편
같은 제1저자의 인용 많은 논문 (5)
- Alkaloids Used as Medicines: Structural Phytochemistry Meets Biodiversity-An Update and Forward Look.
- I SPECT/CT provides prognostic information in patients with differentiated thyroid cancer.
- Consensus Statement on the Outcome of the European Herbal Health Products Summit - Which Way Forward?
- Medicinal plants from the Himalayan region for potential novel antimicrobial and anti-inflammatory skin treatments.
- 25 years after the `Rio Convention'--Lessons learned in the context of sustainable development and protecting indigenous and local knowledge.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- 피나스테리드가 전립선암 발생에 미치는 영향.
- COVID-19의 50가지 이상의 장기 후유증: 체계적 문헌고찰 및 메타분석.
- 양성 전립선 비대증의 임상적 진행에 대한 doxazosin, finasteride 및 병용 요법의 장기 효과.
- 21세기 신약 개발을 위한 천연물: 새로운 신약 발견을 위한 혁신.
- 양성 전립선 비대증 환자에서 finasteride의 효과. The Finasteride Study Group.
- 양성 전립선 비대증 남성에서 급성 요폐의 위험과 수술적 치료 필요성에 대한 finasteride의 효과. Finasteride Long-Term Efficacy and Safety Study Group.